Hepatocellular carcinoma treated with sorafenib: Arterial tumor perfusion in dynamic contrast-enhanced CT as early imaging biomarkers for survival
European Journal of Radiology Nov 09, 2017
Nakamura Y, et al. - Researchers carried out this study to examine whether hepatic perfusion CT yielded early imaging biomarkers predictive of the prognosis of hepatocellular carcinoma (HCC) patients treated with sorafenib. For predicting overall survival in HCC patients treated with sorafenib, hepatic perfusion CT yielded early imaging biomarkers.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
